Lupin Launches Dasatinib in US Market in Partnership with Pharmascience
Mumbai: Global pharma major Lupin Limited has announced the launch of Dasatinib Tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg in the United States, following approval of its Abbreviated New Drug Application (ANDA) by the U.S. FDA. The product was developed in partnership with Pharmascience Inc.
The tablets are bioequivalent to Sprycel® Tablets (Bristol-Myers Squibb) and are indicated for the treatment of:
Headquartered in Mumbai, Lupin is a global pharmaceutical leader with products in over 100 markets. The company specializes in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients, with strong presence in India and the U.S. across multiple therapy areas including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, CNS, and women’s health. Lupin operates 15 manufacturing sites and 7 research centers globally, employing over 24,000 professionals, and drives healthcare impact through subsidiaries: Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Headquartered in Montreal, Pharmascience Inc. is one of Canada’s largest pharmaceutical manufacturers, delivering high-quality medicines to more than 50 countries. The company’s global presence and agile development model support healthcare communities with dependable, Canadian-produced therapies designed to meet evolving patient needs.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.